Pharmaron Beijing revenue and financials
¥44.97Change from previous close: +4.63%Absolute change: +¥1.99
In the fiscal year ended December 2025, Pharmaron Beijing reported revenue of ¥14.1B (+14.82% year over year). Net income was ¥1.66B, a net margin of 11.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14.82%
- 2025 vs 2024
- Net income growth
- −7.22%
- 2025 vs 2024
- Net margin
- 11.8%
- 2024: 14.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 4,017 | 3,578 | 4,009 | — | 3,342 | 3,099 |
| Cost of revenue | 2,695 | 2,416 | 2,552 | — | 2,197 | 2,056 |
| Gross profit | 1,322 | 1,163 | 1,458 | — | 1,145 | 1,043 |
| Selling, general and administrative | -109 | 520 | -701 | — | -127 | 466 |
| Research and development | 156 | 140 | 184 | — | 128 | 122 |
| Operating income | 563 | 496 | 713 | — | 526 | 446 |
| EBIT | 562 | 464 | 635 | — | 499 | 407 |
| EBITDA | 562 | 464 | 635 | — | 499 | 407 |
| Interest expense | 48.4 | 51.6 | 51.1 | — | 50.3 | 43.9 |
| Pre-tax income | 513 | 413 | 584 | — | 449 | 364 |
| Income tax | 112 | 102 | 94.5 | — | 76.2 | 83.9 |
| Net income | 415 | 335 | 523 | — | 396 | 306 |
| Net income to common shareholders | 415 | 335 | 523 | — | 396 | 306 |
| Basic EPS | — | 0.19 | — | — | — | 0.17 |
| Diluted EPS | — | 0.19 | — | — | — | 0.17 |
| Average shares (basic) | — | 1,803 | — | — | — | 1,760 |
| Average shares (diluted) | — | 1,813 | — | — | — | 1,763 |